FONT-SIZE Plus   Neg

Amended: Ampio Pharma Says FDA Accepts IND For Diabetic Macular Edema Drug

Corrects Headline & 1st Para to Indicate FDA Accepts IND for Eye Drug

Ampio Pharmaceuticals, Inc. (AMPE) Tuesday said the FDA has accepted its IND for Optina, an oral drug used in the treatment of diabetic macular edema, or DME.

Optina had been given 505-b-2 status by FDA in July, 2012. Drugs designated under this pathway can be approved on a single trial.

DME is a devastating complication of diabetes and is manifested by local and systemic inflammation. Optina also has the potential to treat other systemic complications of diabetes such as nephropathy, said the company.

The planned multi-center trial, scheduled to begin in the first quarter, is designed to evaluate the safety and efficacy of oral Optina compared with placebo given over a period of 12 weeks in adult patients with DME.

Patients will be randomized to receive one of two doses of Optina per day or placebo. Interim analysis will occur after patients have completed 4 weeks of initial treatment.

Following the 12 week active treatment period, there will be a further 4 week washout period to determine regression of treatment effect.

The primary endpoint is improvement in visual acuity, defined by responder status, compared to placebo, while secondary endpoints include measurements of changes in VA and central macular thickness, tolerability etc.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features. Blaming higher egg prices and other rising costs, Dunkin's Donuts will close 100 stores, all of them Speedway gas station and convenience store locations. Micron Technology, Inc. said that its fourth quarter profit fell 59% from last year, as sales declined and gross margins deteriorated amid weak demand and pricing pressures due to continued softness in the personal computer market. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT